Biotech Gems

02/28/2017 6:00 am EST


Bret Jensen

Editor, Biotech Gems

Aratana Therapeutics (PETX) sold off some 20%as its product Entyce’s rollout will be delayed until the fourth quarter as the company is changing manufacturers.

This does not affect the company’s other two drugs “galliprant” and “nocita” which are just being launched. It should mean less than $10 million in delayed revenues this year from entice.

A $60 million market cap hit was unwarranted and the stock is already starting to recover. I added significantly to my holdings in Aratana on the drop.

Subscribe to Bret Jensen's Biotech Gems here…

  By clicking submit, you agree to our privacy policy & terms of service.

Related Articles on STOCKS